Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New supplement shows promise for hot flashes and hormonal balance

NCT ID NCT07570043

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a daily postbiotic supplement called resW in 80 women aged 35-55 experiencing perimenopause symptoms like hot flashes and mood changes. Participants took either the supplement or a placebo for 4 weeks and completed questionnaires about their symptoms and quality of life. The goal was to see if the supplement could reduce symptom severity and improve hormonal balance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Mar 2026

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 55 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provide voluntary, signed, and dated informed consent. * Female, aged 35 to 55 years, inclusive. * Currently experiencing perimenopausal symptoms, such as hot flashes, mood changes, sleep disturbance, or irregular cycles. * In generally good health as determined by self-reported medical history. * Agree to maintain existing diet, exercise, and lifestyle patterns throughout the study period. * Able and willing to comply with all study procedures, including electronic consent, app-based data entry, and study questionnaires. * Participants selected for the microbiome substudy must be willing to complete stool and vaginal sample collection. * Females of childbearing potential must agree to use a medically acceptable form of birth control during the study. * Agree to refrain from taking other probiotic, prebiotic, postbiotic, hormonal, or menopause-support supplements during the study. * Have reliable internet or smartphone access. Exclusion Criteria: * Currently pregnant, planning to become pregnant, or breastfeeding. * History or current diagnosis of gynecologic disorders or other conditions affecting hormonal balance. * Current or recent use of hormone replacement therapy or hormonal medications. * History of unstable or newly diagnosed cardiovascular, hepatic, renal, or significant metabolic disorders. * Known gastrointestinal disease or condition affecting absorption or metabolism. * Known allergy or sensitivity to any ingredient in the study supplement. * Current participation in another clinical study involving an investigational product or device, or participation in such a study within the past 30 days. * Any other medical or psychiatric condition that, in the opinion of the investigator or study team, could interfere with study participation, compliance, or interpretation of study results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Menopausal symptoms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Able Biolabs LLC

    Dallas, Texas, 75247, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.